CoChat

Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

Open access
Daillère, Romain, Derosa, Lisa, Bonvalet, Mélodie, Segata, Nicola, Routy, Bertrand, Gariboldi, Manuela, Budinská, Eva, De Vries, I. Jolanda M., Naccarati, Alessio Gordon, Zitvogel, Valérie, Caldas, Carlos, Engstrand, Lars, Loibl, Sibylle, Fieschi, Jacques, Heinzerling, Lucie, Kroemer, Guido, Zitvogel, Laurence · 2020 · OncoImmunology
Cited by 38

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Accumulating evidence demonstrates the decisive role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade in preclinical tumor models, as well as in cancer patients. In synthesis, it appears that a normal intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. These findings have led to the design of clinical trials that evaluate the capacity of modulation of the gut microbiota to synergize with treatment and hence limit tumor progression. Along the lines of this Trial Watch, we discuss the rationale for harnessing the gut microbiome in support of cancer therapy and the progress of recent clinical trials testing this new therapeutic paradigm in cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2020.1774298

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 38

Metadata

Authors
Daillère, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budinská, E., De Vries, I. J. M., Naccarati, A. G., Zitvogel, V., Caldas, C., Engstrand, L., Loibl, S., Fieschi, J., Heinzerling, L., Kroemer, G., & Zitvogel, L.
Venue
OncoImmunology
Published
2020-01
Volume
9
Issue
1
Pages
1774298-1774298
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W3033817849
Cited by
38
References
25
FWCI
1.80
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. https://app.cochat.ai/papers/10.1080/2162402x.2020.1774298
The paper
Daillère, R., Derosa, L., Bonvalet, M., Segata, N., Routy, B., Gariboldi, M., Budinská, E., De Vries, I. J. M., Naccarati, A. G., Zitvogel, V., Caldas, C., Engstrand, L., Loibl, S., Fieschi, J., Heinzerling, L., Kroemer, G., & Zitvogel, L. (2020). Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1774298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.